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Endothelin ETB receptor 
heterodimerization:  
beyond the ETA receptor
Erika I. Boesen1
The idea that endothelin ETA and ETB receptors may form 
homodimers and heterodimers has gained increasing interest in 
recent years. The existence of such interactions between endothelin 
receptors has the potential to explain some puzzling results from 
receptor binding and functional studies. Zeng and colleagues take 
ETB receptor heterodimerization beyond the ETA receptor, reporting 
renal endothelin ETB–dopamine D3 receptor interactions at the 
cellular level that appear to have functional consequences in vivo.
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Over the years, a number of studies have 
reported results concerning the behavior 
of the two endothelin receptor subtypes, 
ETA and ETB, that do not fit the classical 
model of two G protein-coupled recep-
tors acting independently of one another. 
For example, in the rat anterior pituitary 
gland, both ETA and ETB receptors are 
expressed, but competitive binding stud-
ies indicated that ETB receptor-selec-
tive ligands competed for binding with 
endothelin-1 (ET-1) only when an ETA 
receptor-selective ligand was present.1 
Simultaneous blockade of both receptor 
subtypes was necessary to inhibit clear-
ance of ET-1 by astrocytes, with antag-
onists of individual receptor subtypes 
having no effect when administered 
alone.2 A similar cooperative interaction 
between the two receptors, necessitating 
blockade of both subtypes in order to 
abolish responses to ET-1, has also been 
noted in a variety of preparations involv-
ing vascular or airway smooth muscle. 
Systematic experiments by Just and col-
leagues3 demonstrated that the contribu-
tions of each receptor subtype to the renal 
vascular effects of ET-1 appear highly 
complex and are not merely additive. This 
may not be surprising given differences in 
receptor expression along the renal vas-
cular tree combined with vasodilator and 
ET-1 clearance functions of endothelial-
cell ETB receptors. However, those factors 
do not adequately explain the observation 
that either an ETA receptor-selective or 
an ETB receptor-selective antagonist was 
able to abolish afferent arteriolar con-
strictor responses to low concentrations 
of ET-1.4
In recent years, there has been much 
interest within the endothelin commu-
nity regarding the possibility that ETA 
and ETB receptors may form homo- 
and heterodimers. Heterodimerization 
of endothelin receptors may provide an 
explanation for the results mentioned 
in the previous paragraph and might 
also account for other reports of atypi-
cal endothelin binding sites, although 
splice variants and post-translational 
modification of receptors should also 
be considered. It has been demonstrated 
with the aid of fluorescence resonance 
energy transfer analysis that, at least in 
transfected cells, ETA and ETB receptors 
can constitutively form heterodimers 
and homodimers.5,6 Furthermore, ETB 
receptors may internalize at a slower 
rate when present as ETA–ETB hetero-
dimers.5 Consistent with this effect, HEK 
293 cells transfected with both ETA and 
ETB receptors display a markedly pro-
longed (>4 minutes) increase in [Ca2+] in 
response to exposure to ET-1 or the selec-
tive ETB receptor antagonist sarafotoxin 
6c, compared with more transient (1–2 
minutes) responses of cells transfected 
with either receptor subtype alone.7
At least with endothelin recep-
tors, most work to date has focused on 
hetero dimerization of ETA and ETB 
receptors, rather than heterodimeri-
zation of endothelin receptors with 
receptors that bind other ligands. How-
ever, multiple combinations of recep-
tor hetero dimers have been described 
over the past 20 years, including dimers 
that bind the same ligand (for example, 
β2-adrenoceptor–α2-adrenoceptor dim-
ers) or different ligands (for example, 
angiotensin AT1–bradykinin B2 receptor 
dimers).7 Heterodimerization of receptors 
alters their ligand-binding properties and 
in some cases appears essential for acti-
vation of downstream signaling.7 Zeng 
and colleagues8 (this issue) now present 
results consistent with the possibility that 
endothelin ETB receptors and dopamine 
D3 receptors form heterodimers in renal 
proximal tubule cells from Wistar–Kyoto 
(WKY) rats. Dopamine receptors have 
previously been shown to heterodimer-
ize with adenosine receptors in neurons, 
allowing adenosine agonists and antago-
nists to modulate the binding affinity and 
signaling activity of dopamine receptors. 
With both D3 and ETB receptors being 
expressed by the proximal tubule, it 
seems plausible that heterodimerization 
of ETB receptors with D3 receptors could 
also occur.
Zeng and colleagues8 report that in a 
proximal tubular cell line derived from 
WKY rats, D3 receptors colocalize with 
ETB receptors in the plasma membrane. 
In contrast, this interaction appears to 
be disrupted in the corresponding cell 
line derived from spontaneously hyper-
tensive rats (SHRs), with ETB receptors 
primarily localized in the cytoplasm and 
D3 receptors present in both the plasma 
membrane and cytoplasm. This difference 
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may be functionally important, as the 
investigators reported that WKY rats pro-
duced a natriuretic response to intrarenal 
infusion of a selective D3 agonist, whereas 
SHRs, at least under conditions of high 
salt intake, did not. Moreover, the natriu-
retic effect of the D3 agonist in WKY rats 
could be attenuated by treatment with an 
ETB receptor antagonist, arguing in favor 
of some kind of functional cross-talk 
existing between ETB and D3 receptors 
in WKY rats. A question not addressed in 
the study is whether the relationship goes 
both ways—do D3 receptor antagonists 
impair the natriuretic effects of tubular 
ETB receptors? Also, what are the effects 
of agonists of D3 and ETB receptors on 
the actions mediated by one another?
This study appears to provide an addi-
tional example, albeit an unanticipated 
one, of the importance of renal ETB 
receptor function in the normal con-
trol of blood pressure and salt and water 
homeostasis. ETB receptor-deficient 
rats, collecting duct-specific ETB recep-
tor knockout mice, and rats chronically 
treated with an ETB receptor antagonist 
all display an elevation of arterial pressure 
that is exaggerated when the animals are 
placed on a high-salt diet. Although these 
effects may be at least partially attribut-
able to loss of ETB receptor-mediated 
NO production, the work of Zeng and 
colleagues8 would suggest that impair-
ment of D3 receptor-induced natriuresis 
might also contribute to the hyperten-
sion observed in those animals. Since D3 
and ETB receptors are both expressed by 
medullary collecting duct cells, it would 
be interesting to know whether collect-
ing duct-specific ETB receptor knockout 
mice display reduced diuretic and natriu-
retic responses to D3 receptor agonists.
Although further experiments are 
needed to determine definitively whether 
D3–ETB receptor heterodimers exist, for 
example, by using fluorescence reso-
nance energy transfer analysis or co-
immunoprecipitation of receptors, the 
results of the study by Zeng and col-
leagues8 appear to indicate that D3–ETB 
receptor interactions in the renal tubules 
facilitate D3 agonist-induced natriure-
sis. Zeng and colleagues have previously 
reported that ETB and AT1 receptors 
can be co-immuno precipitated from 
SHR and WKY renal proximal tubular 
cells.9,10 Although Zeng and colleagues 
reported that stimulation of either the 
ETB or the AT1 receptor resulted in 
changes in expression and phosphoryla-
tion of the other receptor,9,10 the physi-
ological consequences of these ETB–AT1 
receptor interactions were not directly 
addressed. An intriguing possibility is 
that endothelin receptor–AT1 receptor 
heterodimerization could be one of the 
mechanisms underlying the reported 
ability of endothelin receptor antagonists 
to attenuate or abolish acute and chronic 
effects of angiotensin II (see, for exam-
ple, Riggleman et al.11). Several studies 
suggest that ETA receptor activation 
may impair α1-adrenoceptor-mediated 
responses.12,13 However, this appears to 
occur, at least in fibroblasts, via phospho-
rylation of the α1-adrenoceptor,14 and, as 
ET-1 did not stimulate internalization of 
the α1-adrenoceptor, this effect may not 
involve the existence of ETA receptor–α1-
adrenoceptor heterodimers. A pictorial 
summary of the endothelin receptor 
dimers proposed to date is given in 
Figure 1. Whether endothelin receptors 
form hetero dimers with any other recep-
tors, and the functional consequences of 
any such interactions, remains an open 
field of future inquiry.
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figure 1 | Summary of proposed endothelin receptor dimer combinations and the evidence 
in support of their existence. FRET, fluorescence resonance energy transfer.
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